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ABSTRACT 
Cancer is the second leading cause of death worldwide with continues rise mortality rate. Current cancer 
treatment modalities are still ineffective and associated with many side effects leading to robust research 
to find new specific target therapy. Heat shock factor (HSF)-1 is heat shock response mediator protein and 
act as transcription factor for HSP encoding gene. Many cancers have up-regulated HSP as a result of 
increase HSF-1 expression. Interestingly, inhibition of HSF-1 has no effect to normal cell, indicating HSF-1 as 
promises target therapy. RNAi is potential mechanism to block and down regulate HSF-1 which will affect 
many cellular processes in cancer cell. Combining RNAi base treatment with oncolityc viruses will boost the 
therapeutic effect of this novel treatment. Despite its potency, this modality still need further research in 
order to evaluate its efficacy and optimal doses to gain optimal result. 
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INTRODUCTION 
Cancer is second leading cause of death 
worldwide accounting for 13% of all death (7.4 million 
deaths). Deaths from cancer are projected to continue 
rising, with an estimated 12 million deaths in 2030. It 
is estimate that cancer death reach Lung, stomach, 
liver, colon, and breast cancer are the most prevalent 
ones, giving great contribution to total cancer 
mortality rate. Survivability of cancer patient largely 
depends on cancer type in which lung cancer has the 
worst one. But cancer survivability also has inverse 
correlation with cancer stage. Nevertheless, cancer 
has low survivability rate especially in advanced 
stage.
1
The high mortality rate and low rate of 
survivability indicates that current cancer therapy is 
not very effective, especially to treat advanced cancer. 
Current modalities include surgery, radiotherapy, and 
chemotherapy. But these modalities have low efficacy 
and associated with many side effect. For example, 
Radiation can cause esophagitis, induction of 
secondary cancer, radiation related pneumonitis, 
cardiotoxicity (left ventricular heart failure), extremity 
edema, and skin irritation.
2
 Meanwhile chemotherapy 
can induce alopecia, sterility, pancytopenia, nausea 
and vomiting, peripheral neuropathy, and sometimes 
elicit anaphylaxis reaction.
3
 Therefore, ongoing 
research are still conducted in order to find specific 
target for cancer therapy which are non invasive and 
 
Correspondence: Supadmanaba, I G. P. 
Faculty of Medicine Udayana University/Sanglah General 
Hospital, Bali-Indonesia  
Email: supad9@yahoo.co.id 
 
minimal side effect.  HSF-1 is a heat shock response 
mediator protein that acts as transcription factor. 
Upon activation by environmental stress, HSF-1 
dissociate from its cognate binding protein heat shock 
protein (HSP) 90 and HSP70. Dissociated HSF-1 
translocate to the nucleus where it act as transcription 
factor for HSP encoding gene as well as other genes 
that play important role to orchestrate many cellular 
process. Currently, researches show that many 
tumors, including breast, lungs, and colorectal tumor, 
have up regulated HSP that result from HSF-1 over 
expression. Interestingly, inhibition of HSF-1 has no 
effect on normal cell. This phenomenon makes HSF-1 
as a new potential target of cancer treatment.
4
 
RNAi is an efficient gene silencing system. RNAi is 
an evolutionary conserved, gene silencing 
phenomenon which small pieces of double-stranded 
RNA suppress expression of gene with sequence 
homology. This system is mediated by small 
interfering RNA that has capability to recognize 
specific site in target mRNA and degrade it. This 
capability arise when siRNA form a complex with other 
protein to form RISC in cytoplasm. RNAi system is has 
high silencing efficiency, about 100-1000 times more 
powerful than antisense oligonucleotide because 
siRNA is protected within RISC and therefore can act 
as catalyst to degrade many copies of target RNA. 
Currently, RNAi has been applied in cancer 
management. Targeting siRNA to crucial molecule like 
pro-survival gene Bcl-2, growth factor receptor, 
angiogenic gene, and the others would make RNAi to 
be powerful tools to combat cancer cell.
5
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Since most of the proteins depend on HSP in 
order to achieve precise folding, silencing of HSF-1 
gene will down regulate many HSP proteins including 
HSP90 and HSP70 which have wide range of client 
proteins.
5
 HSP down regulation theoretically will bring 
catastrophe effect on cancer cell since it alters many 
cellular processes and signaling. Therefore, targeting 
HSF-1 gene by siRNA will bring crucial implication in 
the development of cancer treatment. By combining 
siRNA with conditioned replicate adenovirus which 
just target cancer cell and spare normal cells will 
further increase the efficiency of this potential therapy 
as well as its safety. 
This review highlights the molecular 
pathogenesis of lung cancer, the role of heat shock 
factor-1 in cancer cells, and general description of 
RNAi. As we progress, there will be description of 
constructing mechanism of adenovirus bearing HSF-1 
RNAi, mechanism of gene silencing by RNAi, and effect 
of HSF-1 down regulation to cancer cells. This review 
end by conclusion and suggestion for further research 
in order to develop RNAi as powerful cancer 
eradication tools in the future.    
 
Role of heat shock factor-1 and heat shock protein in 
cancer cells 
Heat shock factor-1 is heat shock response 
mediator protein. There are three kinds of human HSF 
namely HSF-1, HSF-2, and HSF-4 but HSF-1 is the most 
crucial to HSR. In responses to HSR, HSF-1 activated 
and dissociate from HSP90 and HSP70 (Figure 1). 
Activated HSF-1 translocate to the nucleus where it 
binds with heat-shock element and drives the 
expression of target gene.
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Heat shock response mechanism mediate by HSF-1 and heat shock proteins. HSF-1 be a transcription factor 
for several heat shock proteins (HSP) like HSP90, HSP70, and HSP40. These HSP’s will mediate heat shock 
response either by stabilizing the client protein or guide it to proteosomal degradation 
 
HSF-1 mediates the expression of many heat 
shock protein (HSP). Overall, most important HSP 
regulated by HSF-1 are HSP90, HSP70, and HSP40. 
Many tumors show increase level of HSP which enable 
them to survive in harsh environment and up regulate 
many crucial signaling molecule. HSP promote cell 
survival, growth and metastasis by allowing continued 
protein translation and cellular proliferation. Knocking 
out HSF-1 in mice showed reduced tumor 
development and rendered cultured cell highly 
refractory to transformation initiated by mutated Ras 
or by PDGF-B over expression. 
HSF-1 depletion also decrease viability of 
multiple human cancer lines but has no effect on 
normal cells.
6
 This suggests that HSF-1 provides critical  
 
relieve to cellular stresses experienced by cancer cell. 
Evidence also shows that HSF-1 mediated tumor 
genesis not only by up regulate HSP but also by 
orchestrating a broad network of core cellular 
functions. Therefore, non-oncogene protein that has 
important role in cancer cell but dispensable to 
normal cell, like HSF-1, has become attractive as 
cancer drug targets. 
HSP90 and HSP70 are the two major HSP that 
play important role in cancer. HSP70 is known by its 
powerful anti-apoptotic properties, stronger than any 
known anti-apoptotic agent. In normal condition, 
HSP70 act in assisting peptide folding, assembly of 
multiprotein complex, and transportation of protein 
across cellular membrane.
7
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Related to its function as anti-apoptotic protein, 
HSP70 have many crucial function related to cell 
survivability. HSP70 is known to directly bind 
apoptosis protease-activating factor-1 (APAF-1), 
prevent it to recruit caspase-9 and subsequent 
activation of effector caspases.
8
 It is also known to 
interact with procaspase-3 and 7, preventing their 
maturation. HSP70 inhibit cytochrome-C release from 
mitochondria and inhibit apoptosis inducing factor 
(AIF) thereby preventing induction of apoptosis 
pathway and nuclear fragmentation. In addition, 
caspase activated DNase is also known to regulate by 
HSP70 and HSP40.
9
 
HSP70 has close relationship with pro-survival 
signal transducing pathway like Raf-1/ERK. Its 
cochaperone partner, Bag-1 is known to increase Bcl-2 
anti-apoptotic protein. Overall, HSP70 increase cancer 
cell resistance to apoptosis.
10
 
In addition to HSP70, HSP90 is also one of 
important HSP. Two type of HSP90, HSP90α and 
HSP90β, are essential for viability of eukaryotic cells. 
This protein is quite abundant, comprising about 1-2% 
of cellular protein.
11
  
HSP90 is associates with many signaling protein 
like steroid receptor, ligan independent transcription 
factor like MyoD, tyrosine kinase (v-Src), and 
serine/threonine kinase (Raf-1). It main function is to 
ensure conformational stability of its client protein. In 
order to function properly, HSP90 needs to bind with 
ATP and undergoing conformational change to its 
active form.
12
 
In relation to cancer cell, HSP90 has even more 
important role than HSP70. HSP90 has broad array of 
client protein that play important role in tumorigenic 
process like cell proliferation, growth-signal self 
sufficiency, limitless replication potential, 
angiogenesis, invasion and metastasis (Figure 2). 
Therefore many research and drugs has been 
developed to target this protein. But the result far 
from expected. Some researches reveal that this is 
result from up-regulation of HSP70 in response to 
HSP90 inhibition, rendering HSP90 inhibitors to 
perform their maximal effect.
13,14
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 HSP90 and six hallmark of cancer cell. Among all HSF-1 dependent HSP, HSP90 have the most widespread 
effect because its broad array of client protein. It sustain almost all properties of cancer cell like 
antiapoptosis, self-sufficiency, limitless replication potential, angiogenesis, and tissue invasion as well as 
metastasis.
13,14
 
 
General description of RNA interferences 
RNA interference (RNAi) is an accurate and 
potent gene silencing methods which first 
documented in nematode Caenorhabditis elegans. 
Effector molecules in RNAi are called silencing triggers, 
a nucleic acids that initiate the assembly of protein-
RNA complexes that repress expression of specific 
target genes by reducing their rates of transcription, 
the stability of their mRNA, or the translation of their 
mRNA into protein. The best studied RNAi molecule is 
double stranded RNA which can be produced by 
bidirectional transcription, transcription of inverted 
repeat or “hairpin” sequence, or physically introduced 
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into the cell by injecting, soaking, or even feeding 
dsRNA expressing bacteria.
15
 
siRNA, the effector molecule of RNAi is 21-25 bp 
long RNA. The silencing capability of RNAi is initiated 
by introducing of dsRNA, synthetic siRNA or shRNA 
into cellular target. This small RNA guide silencing 
effector complexes like RNA-induced silencing 
complexes (RISC) or RNA-induced initiation of 
transcriptional gene silencing (RITS) complex. The 
main player in this complex is argonaute family 
protein that act as siRNA docking and also degrade 
target RNA.
16
    
 
Mechanism of construction and delivery of  
HSF1 shRNA 
shRNA is constructed by connecting sense and 
antisense strands of siRNA duplex by loop sequence 
allowing it to fold back when being transcribed. RNA 
polymerase III promoter is often used to drive shRNA 
transcription. Consecutive thymidines are added at 
3’end which will recognize by RNA polymerase III as 
terminator sequence. RNA polymerase promoter U6 
small nuclear RNA and ribonuclease P H1 subunit gene 
are the most frequently used promoters in many 
research to drive shRNA transcription.
17
 They are 
located at 5’end without cis acting regulatory element 
and initiate transcription at single position.
18
 After 
assembling the sequence, shRNA is converted into 
duplex DNA which will insert into viral genome. Highly 
effective shRNA has length ranging from 19-29 nt. But 
shRNA above this range has more effective silencing 
effect probably because increased probability to be 
recognized by dicer or allowing generation of several 
overlapping siRNA.
19
 
The biggest challenge in RNAi therapy is about 
how to effectively deliver siRNA encoding gene into 
cancer cell. Several methods have been developed and 
can be grouped into viral and non-viral-based delivery. 
Non-viral-based delivery consists of direct intravenous 
delivery, lipid-based complex delivery, dynamic 
polyconjugates delivery and protein-conjugation-
based delivery.
20
 But this method is not effective 
because its low bioavailability, require large amount of 
siRNA, and also tend to sequestrate in non-target 
organ like liver and spleen. In contrast, viral-based 
delivery offer some advantage like penetrating ability, 
target cell/organ specificity, and because it deliver 
plasmid containing gene, offer long term effect. Viral-
based delivery also can be sequestrating in non-target 
organ, but recent development of less antigenic viral 
carrier has been solving this problem. In addition, this 
methods is the most suitable to deliver shRNA.
21
 
There some viruses that has been evaluated as 
shRNA delivery vector. They include adenovirus, 
adeno-associated virus, retrovirus, lentivirus, and 
baculovirus.
21
 Among them, adenovirus is the most 
promising one because it is easy to modify its 
genomes and tropism.
22 
 Recent development of 
conditioned replicate adenovirus that restrict 
adenovirus replication just in cancer cell further boost 
its position not just as viral vector but also as 
therapeutic agent.
23
 
Currently, there are 53 serotype of adenovirus in 
human. Among them, adenovirus serotype 5 (Ad.5) of 
species C is the most well characterize. This virus has a 
number of features that make them attractive as a 
platform of oncolityc virus construction. It is not 
associated with any serious disease and its genome is 
well characterized, allowing for relatively easy genetic 
modification. It is also grown in high titer in culture. 
Most importantly, antibody that usually develop 
toward non-replicating adenovirus does not attack 
replicate one, especially Ad.5, which make it relatively 
stable in bloodstream and allowing systemic 
administration to target metastatic tumor.
24
   
Constructions of adenoviral expressing HFS1 
shRNA involve deletion of E3 region and replacing it 
with HSF1 shRNA gene (Figure 3). Adenovirus has E1A 
gene that control viral replication.
25 
The gene is 
preserve but its promoter is replace by PEG-3 
promoter. This promoter is isolated from progressive 
tumor of E11-NMT mice.
26
 E11 is embryonic tumor 
that occurs after mutant serotype 5 adenovirus 
infections. Meanwhile E11-NMT is a product from E11 
clone and selected based on aggressiveness and 
higher proliferation capability. Hybrid subtraction 
technique shows that DNA is C-terminal mutant of 
GADD-34. PEG-3 promoter from minimum region (-
118 until +194) is placed upstream from adenoviral 
E1A gene. PEG-prom is used because of its tumor 
selectivity. This promoter requires transcription 
factors PEA-3 (-104) and AP-1 (+8) which are over 
express only in cancer cell.
 
Ad-PEG-E1A-HSF1shRNA is constructed by using 
2 combinations of shuttle vector, pE1.2 and pE1.3.
27
 
Transgenic band of pE1.2 contains CMV promoter and 
HSF1shRNA meanwhile pE1.3 contain PEG-promoter 
and E1A gene. Both shuttle vectors will be ligated by 
various restriction endonuclease enzymes (AlwNI, 
BstAPI, DraIII, PflMI) at multiple cloning site (MCS) 
which result in cleavage of CMV- HSF1shRNA strand 
and PEG-prom-E1A strand. The product of this process 
is single strand containing PEG-prom-E1A and 
HSF1shRNA. Both of these gene are translocated into 
adenoviral plasmid, yielding Ad.PEG-E1A-HSF1shRNA 
which ready to be processed and infected into target 
cell.  
Because of its small size and immunological 
properties, Ad.PEG-E1A-HSF1shRNA can be 
administered by intratumoral injection, intravenous, 
or inhalation.
28
 Intratumoral injection of adenoviral 
vector has been applied in some research. Sarkar et. 
al. injects 1 x 10
8
 colony forming unit (cfu) into breast 
cancer xenograft (T47D) and prostate cancer (DU-
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145).
29,30
 On the other hand, Luo et. al., administered 
2 x 10
8
 cfu into BEL7404 tumor cells. The viral dose is 
comparable to tumor size but the principle is to infect 
100 pfu to every tumor cell because in this 
concentration 90% of the tumor cell is thought to be 
infected.
31 
 
 
Figure 3 A. Ad.PEG-E1A-HSF1shRNA gene sequences. E3 gene encode capsid protein is replaced by HSF-1shRNA 
encoding gene. The E1A gene that control viral replication is preserve but its promoter is subtituted by PEG-
promoter which enable the virus to replicate specifically in cancer cells.
26
 B Ad.PEG-E1A-HSF1shRNA gene is 
constructed by using shuttle vector pE1.2 carrying PEG-Prom-E1A and pE3.1 carrying HSF-1siRNA which will 
integrate into pAd.
27
 
 
Mechanism of adenovirus homing and its 
internalization to cancer cell 
Adenovirus has icosahedral capsid consist of 
three main proteins (hexon [II], penton base [III], and 
knob fiber [III]). Beside these proteins, there are also 
minor proteins like protein VI, VIII, IX, IIIa, and VIa. 
Adenoviral infection can be divided into 2 phases, 
initial phases where adenovirus enter the cell and 
translocate its genome to the nucleus.  Second  phase, 
which called end phases consist of viral genome 
expression (PEG-E1A-HSF1 siRNA).
32
 
Internalization of serotype-5 adenovirus is 
mediated by coxsackie and adenovirus receptor (CAR), 
integrin, and heparan sulfate glycosaminoglycan (HS-
GAGs) (Figure 4). Internalization process is initiated by 
formation of RGD peptide bond between penton base 
with integrin from αvβ3 and αvβ5 vitronecti receptor 
family. This complex activate phosphoinositide (PI) 3-
kinase, p130
CAS
, Rho GTPase, dan Raf/mitogen 
activated protein kinase (MAPK).
33
 These molecules 
induce actin rearrangement in the intracellular surface 
of plasma membrane which will mediate adenoviral 
internalization. Peptide complex RGD and integrin 
facilitate the formation of high affinity binding 
between fiber knob and CAR. CAR is 46 kDa trans 
membrane protein and belongs to immunoglobulin 
family. This interaction releases virus into cytoplasm. 
Then protease will degrade protein VI, which connect 
capsid with core protein, and freeing viral core 
component. Viral genome will set its way to the 
nucleus. This process is mediated either by viral core 
protein (TP protein, protein V, VII, and μ-peptide) and 
cellular protein p32. p32 is thought to mediate cellular 
transportation between nucleus and mitochondria but 
can also mediate viral genome translocation.
34
 
In the nucleus, viral genome is directed to 
nuclear matrix where TP protein forms a complex with 
CAD pyrimidine. Then, the lamin B protein complexes 
with p32 which dissociates viral DNA from p32. The 
viral genome integrates with host genome and ready 
to be express by transcription and translation.
35,36
   
 
Mechanism of HSF-1 gene silencing by shRNA 
As tumor cell express the viral protein, it also 
express siRNA gene in viral genome. shRNA gene is 
expression is same like common transcriptional model 
but it will fold as a result from folding strand within it. 
shRNA then being transported from nucleus to the 
cytoplasm by exportin-5. In cytoplasm, shRNA will 
cleave by dicer, a type III ribonuclease. This yield a 
small 21 nucleotide double stranded RNA composed 
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of two stranded, guide stranded and passenger 
stranded. Strand selection is dictated by 
thermodynamic stability in which guide strand is 
located at less stably base pair in 5’end.
37
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Adenovirus internalization process. Internalization process begin with binding of viral fiber knob with CAR 
and integrin. After internalization, viral release and capsid degradation ensue until viral genome set it way 
into the nucleus.
33
 
 
In cytoplasm, double stranded siRNA forms a complex 
with Dcr-2 and R2D2. This complex is called RNA-
induced silencing complex (RISC) loading complex 
(RLC) (Figure 5). RLC function to unwind dssiRNA, 
releasing guide strand from passenger strand which 
will be degraded. Then, siRNA will be recruited into 
holo-RISC a large protein complex containing TSN, Dcr-
1, VIG, dFMR1, and Ago2. This recruitment is mediated 
by Dcr-2 and R2D2 interaction. The PAZ domain of 
Ago2 recognizes 3’ end of siRNA and begin to unwind 
dssiRNA, cleave the passenger strand and eject it from 
complex. The final product is functional 80S RISC that 
has capability to cleave target RNA.
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Mechanism of integration of siRNA into RISC complex. After clevage, double-stranded siRNA congregate with 
proteins likeDcr-2 and R2D2, forming RISC complex. With subsequent dissociation of guide strand, RISC is 
activated ready to degrade target mRNA. 
38
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Once loaded into RISC, small RNA guides at least three 
distinct mode of silencing (Figure 6).
39,40
 Most often, 
small RNA will direct RISC to target mRNA and its 5’ 
half will form base pairing complementary the target 
mRNA. Next, piwi domain of Ago2 protein will catalyze 
cleavage process. This domain has structural homolog 
with RNase H and requires Mg
2+
 as cofactor. The 
cleavage process is very precise: phosphodiesterase 
activity is mediated at siRNA residues 10 and 11 (from 
5’end) producing 5’monophosphate and 3’hydroxil 
terminus. These fragments are subject of 
oligouridylation process and can mediate 
exonucleolytic targeting which will complete the 
degradation process. After cleavage of target mRNA is 
complete, siRNA depart intact with RISC and guide it 
to the next target mRNA. This shows that RISC is a 
multiple turnover enzyme.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Mechanism of gene silencing by siRNA. siRNA shut down gene expression by several mechanism. Most 
notably is degradation of target mRNA which have fully complementer sequence to it. It also able to alter 
gene transcription by induce heterochromatin formation or disrupt translational process if there are some 
mismatch between siRNA and target mRNA 
15
 
 
siRNA is not always complement the target mRNA 
completely. Sometimes, it partially mismatches. Partial 
mismatch between siRNA and mRNA suppress the 
endonucleolytic activity of PIWI domain of Ago2. 
siRNA still capable to suppress gene expression but by 
using different mechanism. The post transcriptional 
silencing mechanism mediated by RISC is the same 
between siRNA and miRNA. The precise mechanism is 
still on debate but there are three proposed 
mechanisms. First, RISC probably competes with eIF4E 
for binding in mRNA 5’cap. Without eIF4E, initiation of 
transcription  will  not occur. Second,  RISC  stimulate  
 
dead-enylation of mRNA tail. In this case, translation is 
suppress because the cap and PABP-1 free tail of 
deadenylate mRNA is unable to circularize. The last 
proposed mechanism stated that RISC block 
association of 60 S ribosomal subunit with 40 S 
preinitiation complex. This result from physical 
interaction between human Ago2 with eIF6 (which 
function in 60 S ribosomal subunit biogenesis and 
maturation and prevent premature association 
between 60 S and 40 S) and 40S ribosomal subunit.
41  
Finally, siRNA also capable to suppresses gene 
expression in transcriptional level by forming 
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repressive heterochromatin.
42
 In this case, siRNA form 
another complex called RNA-induced initiation of 
transcriptional gene silencing (RITS) consist of Ago1 
and chromodomain protein Chp1 and Tas3. siRNA 
guide RITS complex to specific chromosomal loci such 
as centromere repeats. Then, nascent transcript will 
be recognizing by siRNA, facilitated by direct 
interaction between RITS and RNA polymerase II. This 
association promotes hystone H3 methylation on 
lysine 9 (H3K9) by hystone methyl transferase (HMT) 
meading to recruitment of chromodomain containing 
swi6 and chromatin compaction. Engagement of 
nascent transcript by siRNA also activates RNA-
dependent RNA polymerase complex (RORC). RORC 
has RdRP subunit which will produce secondary siRNA 
and reinforce gene silencing 
siRNA is very effective in knocking down the 
target gene and even in small amount can completely 
shut down the expression of target gene. This will 
result in complete down regulation of HSF-1. Since 
HSF-1 act as primary transcription factor for HSP90, 
HSP70, and HSP40, it absence will result in complete 
silencing of those gene. This means cancer cells will 
not be able to mount heat shock response, lost many 
functional proteins, and succumb from accumulation 
of miss folded protein which finally drives the cell to 
apoptosis. 
 
Effect of HSF-1 gene silencing to cancer cell 
The direct effect of HSF-1 gene silencing is 
complete down regulation of its target gene like 
HSP90, HSP70, and HSP40.
6
 Since heat shock proteins 
are important to guide protein folding, their absence 
will result in miss folding of their client protein. 
Because HSP90 and HSP70 are the two major heat 
shock protein, their absence will shut down heat shock 
response completely. 
Off all HSP, HSP90 is the most important in many 
solid tumor as well as hematological malignancy.
14
 
HSP90 has wide variety of client protein that have 
important role in cell survival, proliferation, expression 
of growth factor receptor, invasion, and metastasis. 
Because of that, most of the effect of HSF-1 down 
regulation is likely caused by HSP90 down regulation. 
 
Alteration of tumor survivability 
Cancer cells live in harsh hypoxic and nutrient 
deprived environment where normal cell will not 
survive.
3
 This is because cancer cells over express 
some of the protein that play important role in cell 
survivability.  AKT, Raf, and epidermal growth factor 
receptor (EGFR) are protein that mediate cancer 
survivability.
43
 AKT and Raf act as relay protein 
downstream from tyrosine kinase receptor and G-
protein coupled receptor. Because most growth 
factors receptor is tyrosine kinase receptor, it is likely 
that these protein mediate many prosurvival signal 
elicited by growth factors receptor.  
EGFR is one of growth factor receptor. EGFR is up 
regulated in 10% to 40% of lung adenocarcinoma.
44
 
This receptor is also upregulated in small cell lung 
carcinoma whether in lower frequency. Most of the 
mutation occurs in kinase properties of the receptor 
so it can activate itself even in the absence of signal. 
This receptor mediated prosurvival signaling by PI3K-
AKT pathway. 
AKT, EGFR, and Raf are client protein of HSP90. 
Down regulation of HSP90 results in missfolding of 
these protein which make them non-functional. PI3K-
AKT pathway is known play important role in 
regulation of Bcl-2 and Bcl-xL prosurvival protein so 
down regulation of this signaling pathway will make 
cancer cell more vulnerable to apoptosis induction.
44
 
Down regulation of EGFR also contribute in apoptosis 
sensitization in cancer cell because it will decrease 
stimulation to PI3K-AKT and Ras-Raf signaling 
pathway. 
HSP-70 down regulation also has very significant 
effect on apoptosis induction because HSP70 is known 
as powerful anti-apoptotic agent.
8
 HSP70 inhibit many 
important proteins in apoptosis pathway include 
caspase-3,-7,and -9, APAF-1, apoptosis inducing factor 
(AIF), caspase-induced DNase (CAD), as well as c-Jun 
N-terminal kinase (JNK) mediated pathway. In 
addition, HSP70 cochaperone Bag-1 increase activity 
of Bcl-2 and Raf-1/ERK signaling pathway that prefer 
cell survivability. Therefore, down regulation of HSP70 
will ablate the inhibition toward apoptosis pathways 
as well as decrease prosurvival molecule such as Bcl-2 
which make cancer cell very vulnerable to apoptosis.  
Induction of unfolded protein responses and apoptosis 
HSF-1 gene silencing will result in almost complete 
halt in its expression. The absence of HSF-1 impairs 
the cancer cell to mount HSR as a result from decrease 
expression of HSP90, HSP70, and HSP40. These HSP 
are the major chaperones that act to rescue the 
folding process of many proteins. Thus it absence will 
result in accumulation of missfolded protein either in 
cytoplasm and endoplasmic reticulum. 
Accumulation of miss folded proteins trigger the 
activation of a process known as unfolded protein 
response (UPR).
45
 Unfolded proteins will bind Bip 
which formerly associated with three inactive UPR 
sensors activating transcription factor-6 (ATF6), 
inositol-requiring enzyme -1 (IRE1), and PKR-like ER 
protein kinase (PERK).
46
 When Bip dissociate from 
them, it activate these protein, elicit UPR signaling 
pathway. Activated PERK dimerises and 
autophosphorilate and activate eukaryotic translation 
initiation factor 2 α subunit (eIF2α). This protein will 
halt general translational process and also 
phosphorilate ATF4.
47
 On the other hand, IRE1 posses 
RNase activity and cleave 26 bp intron from X-box-
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binding protein 1 (XBP1) mRNA enabling it to be 
translated into functional protein. Meanwhile, ATF6 
transits to the cis-golgi compartment where it cleaves 
by site-1 protease (S1P) and site-2 protease (S2P). The 
cleaved N-terminal translocate to the nucleus where, 
together with ATF4 and XBP1, it activate transcription 
of UPR response gene.  
In addition to UPR, missfolded proteins also 
trigger apoptosis mediated by UPR sensors described 
above.
47
 IRE1 will recruit c-Jun-N-terminal inhibitory 
kinase (JIK) and TRAF2. These complex activated 
ASK1/JNK signaling pathway that drive the apoptosis 
process. Recruitment of TRAF2 also releases 
procaspase-12 from ER. When convert into its active 
form, caspase-12 will cleaved procaspase-9 into 
caspase-9. Next, caspase-9 will mediated cleavage of 
effectors caspase like caspase-3, caspase-7, and 
caspase-10. 
On the other hand, ER stress, resulting from 
excessive accumulation of missfolded proteins, induce 
conformational alteration of Bax and Bak which allows 
Ca
2+
 ion to diffuse out from ER.
46
 Ca
2+
 bind to 
associated protein m-calpain which will cleave 
procaspase-12 into caspase-12. Ca
2+
 also induces 
mitochondria-dependent apoptosis by releasing 
cytochrome-c to cytoplasm and allowing it to form 
APAF-1 with caspase-9 and activate effectors 
caspases. Meanwhile, activated PERK and ATF6 
phosphorilate CEBP homologous protein (CHOP) which 
will down regulate Bcl-2, thus increase the 
vulnerability of cancer cell to apoptosis.  
 
Inhibition of angiogenesis 
Angiogenesis is important event that ensure 
tumor survivability once it reach certain size. Hypoxia-
inducible factor-1 (HIF-1) is the chief regulator of 
many angiogenic genes.
48
 This protein consists of 2 
subunits. Alpha subunit is the oxygen sensing 
meanwhile β-subunit is constitutively expressed. 
Alpha subunit will dimerises with β-subunit before it 
translocates into nucleus and induce transcriptional 
process of many angiogenic genes. 
HSF-1 is HSP90 client protein and it down 
regulation prevents HIF-1 folding into functional 
protein and directing it to proteasomal degradation. 
Decrease number of HIF-1 result in decrease 
expression of important angiogenic mediator like nitric 
oxide synthase (NOS) and vascular endothelial growth 
factor (VEGF), thus prevent increase in vascular 
permeability and endothelial cells migration. There are 
also down regulation in matrix metalloproteinase-2 
(MMP-2) and urokinase-type plasminogen activator 
receptor that function in cellular matrix metabolism. 
Two glycolysis enzymes, phosphoglycerate kinase-1 
and lactate dehidrogenase are also down regulate 
since their genes are regulate by HSF-1, thus decrease 
the ability of cancer cells to survive in hypoxic 
condition.
49
 Overall, down regulation of HSP90 result 
in nonfunctional HSF-1 which result in angiogenesis 
inhibition from many cellular aspects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Summary of the effect of HSF-1 gene silencing by shRNA to cancer cell. Because HSF-1 is the main 
transcription factor for major HSP’s, it have broad array of effects that disrupt almost all properties of 
cancer cell.
6,8,14
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Inhibition of Cell Proliferation 
Cancer cell retain capability to proliferate 
excessively as result from up regulation of cell cycle 
regulated protein cyclin-dependent kinase (CDK) or 
signaling molecule that influence it. In addition other 
cell cycle regulator like retinoblastoma and E2F are 
also takes a part. Retinoblastoma is regulated by CDK4 
and when phosphorilate, it release E2F which will 
activate cell cycle progression from G1 to S phase.  
In addition, cancer cell usually over express 
human telomerase reverse transcriptase (hTERT) that 
will maintain the length of the telomere and enable 
cancer cell to proliferate excessively without reduce it 
chromatin length.
50
 
Down regulation of HSP90 as a result of decrease 
expression of HSF-1 targets CDK4 to proteasomal 
degradation.
51
 Non functional CDK4 loses its ability to 
phosphorilate Rb, preventing its dissociation from E2F. 
As result, cancer cell will remain in G1 phase and 
unable to progress into S phase, prevent it to 
proliferate. In addition, non functional hTERT result in 
progressive shortening of the telomere and limit the 
cancer cell proliferation potential.
52
 Thus, HSF-1 gene 
silencing is able to inhibit cell division by targetting 
CDK4 and hTERT to proteasomal degradation. 
 
Inhibition of cancer cell invasion and metastasis 
HSP90 client protein, proto-oncogenes Met and 
MMP-2 are required for metastatic process. Gene 
product of Met, p190
Met
 is a hepatocyte growth 
factor/scatter factor (HGF/SF) receptor. Activation of 
this receptor increase cellular proliferation, migration, 
and invasion of cancer cells. Metastasis also requires 
cell adhesion to extracellular matrix, digestion of the 
matrix, and migration of the cancer cells. These 
processes are mediated by MMP-2. Down regulation 
of HSP90 decrease the number of active p190
Met 
and 
impair MMP-2 maturation which will inhibit cancer 
cell invasion and metastasis.
53
 
 
CONCLUSION 
HSF-1 plays a crucial role in lung cancer cell to 
maintain many cellular processes and signaling. HSF-1 
mediates its effect by acting as transcription factor 
that regulate HSP encoding gene as well as molecules 
that orchestrating many cellular process. HSF-1 siRNA 
is integrated into adenovirus genome, which will act as 
carrier and cancer terminator virus. siRNA silence HSF-
1 gene by forming RISC complex which will recognize 
and degrade HSF-1 mRNA. siRNA also capable to halt 
transcription process of HSF-1 mRNA and direct 
silencing HSF-1 by induce the the formation of 
heterochromatin. Silencing of HSF-1 by siRNA will 
bring catastrophic effect to cancer cell since it halts 
prosurvival signaling, induce apoptosis, inhibit cell 
proliferation, and inhibit angiogenesis as well as 
invasion and metastasis as a result from HSP down 
regulation. Despite its broad array of promising effect, 
application of HSF-1 siRNA in cancer treatment still 
need further research in order to confirm its efficacy 
and establish the optimal dose required to elicit its 
effect.  
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